TET2 and myelodysplastic syndrome: Although somatic mutations are less frequent in blood malignancies compared to solid tumors (87), they often can be linked to altered gene function implicated in tumorigenesis such as mutations in TET2 (88), DNMT3A (89) (MDS/AML), SF3B1 (90, 91) (CLL, MDS) or JAK2 (92) (MPN) and acquired therapeutic resistance (BCR-ABLT315i, BTKC481S, PLCG2R665W) (93, 94) (Figure 1D).